RxDoctor Payments Data

Mikhail Shkiryak

Nurse Practitioner · Iowa City, IANPI 1750867248

Payments from drug & device makers

$1,673in general payments, 2019–2025

Across 21 payments — averaging $79.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • Biogen$131
  • Jazz Pharmaceuticals Inc.$92
  • AbbVie$56
  • Lilly USA, LLC$30
  • Biohaven Pharmaceuticals, Inc.$17
  • plus $54 from 4 others

What the payments were for

  • Travel & lodging$99259%
  • Food & beverage$68141%

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,673 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$20,967
Medicare patients
179
Services billed
346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam396$548,260
AptiomEslicarbazepine Acetate225$429,062
XcopriCenobamate181$235,967
EpidiolexCannabidiol (Cbd)35$188,941
Rufinamide80$165,943
KeppraLevetiracetam54$128,356
BanzelRufinamide17$120,960
NayzilamMidazolam95$101,916
OnfiClobazam24$91,230
TopamaxTopiramate53$77,681
VimpatLacosamide60$77,469
Lacosamide535$72,300
UbrelvyUbrogepant50$67,023
LamictalLamotrigine40$63,763
Nurtec OdtRimegepant Sulfate48$53,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$13$235,967181 claims
AbbVieUbrelvy, Qulipta$56$80,40662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →